Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer

Journal of Urology

Volumn 157, Issue 2, 1997, Pages 492-498

  Zlotta, Alexandre R ^a   Drowart, Annie ^a   Van Vooren, Jean Paul ^a   De Cock, Michel ^a   Pirson, Michel ^a   Palfliet, Kamiel ^a   Jurion, Fabienne ^a   Vanonckelen, Albert ^a   Simon, Jacques ^a   Schulman, Claude C ^a   Huygen, Kris ^a  

^a PASTEUR INSTITUTE OF BRUSSELS   (Belgium)

Author keywords

BCG vaccine; bladder neoplasms; cytokines; fibronectins; receptors, antigen, T cell

Indexed keywords

BCG VACCINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0031013477     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)65185-1     Document Type: Article

References (29)

1. Lamm, D. L.: Long-term results of intravesical therapy for superficial bladder cancer. Urol. Clin. N. Amer., 19: 573, 1992.
2. Nadler, R. B., Catalona, W. J., Hudson, M. A. and Ratlif, T. L.: Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J. Urol., 152: 367, 1994.
3. Ratliff, T. L., Ritchey, J. K., Yuan, J. J., Andriole, G. L. and Catalona, W. J.: T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J. Urol., 150: 1018, 1993.
4. Thanhauser, A., Böhle, A., Schneider, B., Reiling, N., Mattern, T., Ernst, M., Flad, H. D. and Ulmer, A. J.: The induction of bacillus-Calmette-Guerin activated killer cells requires the presence of monocytes and T-helper type-1 cells. Cancer Immun. Immunother., 40: 103, 1995.
5. Böhle, A., Nowc, Ch., Ulmer, A. J., Musehold, J., Gerdes, J., Hofstetter, A. G. and Flad, H. D.: Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guerin immunotherapy. J. Urol., 144: 59, 1990.
6. Böhle, A., Gerdes, J., Ulmer, A. J., Hofstetter, A. G. and Flad, H. D.: Effects of local bacillus Calmette-Guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J. Urol., 144: 53, 1990.
7. Klegerman, M. E., Muhammad, A. S., Groves, M. J., Shaw, M. and Guinan, P.: Efficacy of a BCG glycan preparation, PS1, in two animal bladder cancer models. J. Urol., part 2, 153: 487A, abstract 1036, 1995.
8. Kavoussi, L. R., Brown, E. J., Ritchey, J. K. and Ratliff, T. L.: Fibronectin mediated bacille Calmette-Guerin attachment to murine bladder mucosa: requirement for expression of an antitumor response. J. Clin. Invest., 85: 62, 1990.
9. Wiker, H. G. and Harboe, M.: The antigen 85 complex: a major secretion product of Mycobacterium tuberculosis. Microbiol. Rev., 56: 648, 1992.
10. Content, J., de la Cuvellerie, A., De Wit, L., Vincent-Levy-Frébault, V., Ooms, J. and De Bruyn, J.: The genes coding for the antigen 85-complex of M. tuberculosis and M. bovis BCG are members of a gene family: cloning, sequence determination and genomic organization of the gene coding for the antigen 85-C of M. tuberculosis. Infect. Immun., 59: 3205, 1991.
11. Launois, P., Niang, M. N., De Bruyn, J., Sarthou, J. L., Rivier, F., Drowart, A., Van Vooren, J. P., Millan, J. and Huygen, K.: The major secreted antigen complex (AG 85) from M. bovis bacille Calmette-Guerin is associated with protective T-cells in leprosy: a follow-up study of 45 household contacts. J. Infect. Dis., 167: 1160, 1993.
12. Huygen, K., Van Vooren, J. P., Turneer, M., Bosmans, R., Dierckx, P. and De Bruyn, J.: Specific lymphoproliferation, gamma interferon production and serum immunoglobulin G directed against a purified 32 kDa mycobacterial protein antigen (P32) in patients with active tuberculosis. Scand. J. Immunol., 27: 187, 1988.
13. Lamm, D. L., Van der Meijden, A. D. P. M., Morales, A., Brosman, S. A., Catalona, W. J., Herr, H. W., Soloway, M. S., Steg, A. and Debruyne, F. M. J.: Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J. Urol., 147: 596, 1992.
14. Fleischmann, J. D., Moonja-Chung, P. and Hassan, M. O.: Fibronectin expression on surgical specimens correlated with the response to intravesical bacillus Calmette-Guerin therapy. J. Urol., 149: 268, 1993.
15. Launois, P., DeLeys, R., Niang, M. N., Drowart, A., Andrien, M., Dierckx, P., Cartel, J. L., Sarthou, J. L., Van Vooren, J. P. and Huygen, K.: T-cell-epitope mapping of the major secreted mycobacterial antigen Ag85A in tuberculosis and leprosy. Infect. Immun., 62: 3679, 1994.
16. Huygen, K., Abramowicz, D., Vandenbussche, P., Jacobs, F., De Bruyn, J., Kentos, A., Van Vooren, J. P. and Goldman, M.: Spleen cell cytokine secretion in M. bovis BCG-infected mice. Infect. Immun., 60: 2880, 1992.
17. Nathan, C. F., Murray, H. W., Wiebe, M. E. and Rubin, B. Y.: Identification of interferon-gamma as the lymphokine that activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med., 158: 670, 1983.
18. Hawkyard, S., James, K., Prescott, S., Jackson, A. M., Ritchie, A. W. S., Smyth, J. F. and Chisolm, G. D.: The effects of recombinant human interferon-gamma on a panel of human bladder cancer cell lines. J. Urol., 145: 1078, 1991.
19. Orme, I.: Immunity to mycobacteria. Curr. Opin. Immunol., 5: 497, 1993.
20. Kelley, D. R., Ratliff, T. L., Catalona, W. J., Shapiro, A., Lage, J. M., Bauer, W. C., Haaf, E. O. and Dresner, S. M.: Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results. J. Urol., 134: 48, 1985.
21. Teppema, J. S., de Boer, E. C., Steerenberg, P. A. and van der Meijden, A. P.: Morphological aspects of the interaction of bacillus Calmette-Guerin with urothelial bladder cells in vivo and in vitro: relevance for antitumor activity? Urol. Res., 20: 219, 1992.
22. Manca, F., Rossi, G., Valle, M. T., Lantero, S., Li Pira, G., Fenoglio, D., De Bruyn, J., Costantini, M., Damiani, G., Balbi, B. and Celada, F.: Limited clonal heterogeneity of antigen-specific T cells localizing in the pleural space during mycobacterial infection. Infect. Immun., 59: 503, 1991.
23. Lamm, D. L.: BCG in perspective: advances in the treatment of superficial bladder cancer. Eur. Urol., suppl. 1, 27: 2, 1995.
24. Böhle, A., Gerdes, J., Nowc, C., Ulmer, A. J., Musehold, J., Hofstetter, A. G. and Flad, H. D.: Effects of local BCG therapy in patients with bladder carcinoma on phenotypes and function of mononuclear cells. In: Immunotherapy of Urological Tumours, International Society of Urology Reports. Edited by J. B. deKernion. New York: Churchill Livingstone, p. 83, 1990.
25. Schmidt, A. C., Bouic, P. J., Heyns, C. F. and De Kock, M. L.: Peripheral blood lymphocyte response in patients with superficial transitional cell carcinoma of the bladder treated with intravesical bacillus Calmette-Guerin - a useful marker of response? Brit. J. Urol., 71: 179, 1993.
26. De Reijke, T. M., De Boer, E. C., Kurth, K. H. and Schammart, D. H. J.: Urinary cytokines during intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: processing, stability and prognostic value. J. Urol., 155: 477, 1996.
27. Mituzani, Y., Okada, Y., Terachi, T. and Yoshida, O.: Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer. J. Urol., 155: 888, 1996.
28. Liu, B. C. and Liotta, L. A.: Biochemistry of bladder cancer invasion and metastasis. Clinical implications. Urol. Clin. N. Amer., 19: 621, 1992.
29. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E. and Jacks, T.: p53 status and the efficacy of cancer therapy in vivo. Science, 266: 807, 1994.